Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M Accessibility StatementSkip Navigation Throughout the year, we continued to demonstrate resilience and solid profitability, while further strengthening the Company's balance sheet. Looking ahead, we are making strong progress toward the next key milestone: a U.S. public offering, aimed at creating value for our investors." Our pharmaceutical segment is dedicated to developing innovative, non-opioid solutions for chronic pain manag ...

- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. "This past year was defined b ...

Core Viewpoint - Eupraxia Pharmaceuticals Inc. reported significant clinical milestones and financial results for Q4 2025, indicating a strong position for future growth and development of its lead program, EP-104GI [2][4]. Financial Performance - The company incurred a net loss of $16.7 million in Q4 2025, compared to a net loss of $7.5 million in Q4 2024, primarily due to increased research and development costs for the EP-104GI program and higher general and administrative expenses [4]. - As of December 31, 2025, Eupraxia had cash reserves of $80.5 million, up from $33.1 million at the end of Q4 2024, which is expected to fund operations into the second half of 2028 [5]. Operational Highlights - Eupraxia achieved key clinical milestones in 2025, including positive follow-up data from the RESOLVE trial for eosinophilic esophagitis (EoE) and the completion of a Phase 2b trial for EP-104IAR [9][12]. - The company anticipates multiple clinical readouts from the ongoing RESOLVE trial and plans to initiate additional clinical programs to expand its pipeline [2]. Technology and Product Development - Eupraxia's proprietary Diffusphere™ technology is designed for optimized local drug delivery, targeting therapeutic areas with high unmet medical needs, including pain and inflammatory gastrointestinal diseases [11]. - The company is developing EP-104GI, which is currently in a Phase 1b/2 trial for EoE, and has plans for further long-acting formulations targeting other inflammatory conditions and oncology [12]. Market and Trade Considerations - Management is monitoring the North American trade situation, particularly the impact of proposed tariffs on imported goods, which could affect the company's operations and costs [6][8]. - Eupraxia manufactures its clinical supplies in the U.S. and maintains U.S. dollar balances to mitigate exchange rate fluctuations [7].

Core Viewpoint - Eupraxia Pharmaceuticals Inc. has announced a public offering of common shares and pre-funded warrants, aiming to raise approximately US$55 million to advance its clinical programs and expand its pipeline [1][3]. Group 1: Offering Details - The public offering consists of 6,428,574 common shares priced at US$7.00 each and pre-funded warrants to purchase up to 1,428,571 common shares at US$6.99999 each, resulting in gross proceeds of about US$55 million before expenses [1]. - The offering is expected to close on February 20, 2026, pending customary closing conditions, including the listing of shares on the TSX and Nasdaq [1]. - Underwriters have a 30-day option to purchase an additional 1,178,571 common shares under the same terms [1]. Group 2: Use of Proceeds - The net proceeds will primarily fund the advancement of EP-104GI for Eosinophilic Esophagitis, including ongoing preclinical studies and Phase 2 clinical trials, as well as preparations for a Phase 3 trial [3]. - A portion of the funds will be allocated to expand clinical studies for EP-104GI in additional gastrointestinal indications and to support research and development of other pipeline candidates [3]. - The proceeds may also be used for general corporate purposes, including employee salaries, working capital, and expanding the intellectual property portfolio [3]. Group 3: Company Overview - Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products targeting high unmet medical needs [7]. - The company utilizes its proprietary Diffusphere™ technology for optimized local drug delivery [7].

Halozyme Therapeutics, Inc. 1 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance and growth rates (including the Company's 2026 financial guidance and longer term financial outlook through 2028 and the assumptions used in deriving such guidance and longer term financial outlook) including expectations for futu ...

Core Insights - Halozyme Therapeutics reported record total revenue of $1.4 billion for the full year 2025, representing a 38% year-over-year increase, driven by significant growth in royalty revenue and product sales [1][2][3] - The company reiterated its strong financial guidance for 2026, projecting total revenue between $1.710 billion and $1.810 billion, with year-over-year growth of 22% to 30% [1][3] - Halozyme expanded its drug delivery technology portfolio through acquisitions of Elektrofi and Surf Bio, enhancing its long-term royalty opportunities [1][2][3] Financial Performance - Full year 2025 royalty revenue reached a record $868 million, a 52% increase from 2024, primarily due to the success of ENHANZE-enabled products [1][2] - Fourth quarter 2025 total revenue was $451.8 million, up 52% from $298.0 million in the same quarter of 2024, with royalties contributing $258.0 million [2][5] - The company reported a net loss of $141.6 million in Q4 2025, compared to a net income of $137.0 million in Q4 2024, largely due to acquired in-process research and development expenses [2][5] 2026 Financial Guidance - Halozyme expects non-GAAP diluted earnings per share for 2026 to be between $7.75 and $8.25, reflecting growth of 87% to 99% over 2025 [1][3] - Adjusted EBITDA is projected to be between $1.125 billion and $1.205 billion, indicating growth of 71% to 83% over the previous year [1][3] - Royalty revenue for 2026 is anticipated to be between $1.130 billion and $1.170 billion, representing a growth of 30% to 35% compared to 2025 [3] Corporate Developments - In November 2025, Halozyme completed the acquisition of Elektrofi, enhancing its drug delivery technology portfolio [1][2] - The company also acquired Surf Bio in December 2025, further expanding its capabilities in drug delivery technologies [1][2] - Halozyme entered into multiple collaboration agreements with partners such as Takeda and Merus, broadening its market reach and product offerings [1][2]

Market Overview - The global Peptide Therapeutics Market was valued at USD 46.04 billion in 2024 and is projected to reach USD 82.19 billion by 2032, with a CAGR of 7.51% from 2025 to 2032 driven by demand for targeted medications in oncology, metabolic diseases, and infectious diseases [1][17]. U.S. Market Insights - The U.S. peptide therapeutics market was valued at USD 20.36 billion in 2024 and is expected to grow to USD 35.71 billion by 2032, with a CAGR of 7.27% during the same period, supported by significant R&D expenditure and regulatory frameworks [2]. Technological Advancements - Innovations in peptide synthesis and drug delivery technologies, such as solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS), are enhancing manufacturing efficiency, purity, and scalability [4]. - Advances in delivery platforms, including sustained-release formulations and nanoparticles, are improving the stability and usability of peptide medications [4]. Market Challenges - High production costs and complex manufacturing processes pose challenges for the development of peptide therapeutics, as synthesis and purification require expensive equipment and high-purity reagents [5]. Market Segmentation By Application - The metabolic disorders segment held a 26.2% market share in 2024, driven by the prevalence of diseases like type 2 diabetes and obesity, while the pain segment is expected to grow at the highest CAGR due to rising chronic pain disorders [7]. By Therapeutics Type - The innovative segment dominated the market in 2024, reflecting the demand for high-activity and targeted treatment options [8]. By Type of Manufacturers - The in-house segment accounted for 65.25% of the market share in 2024, as major companies prefer control over the drug development process, while the outsourced segment is anticipated to grow at the highest CAGR [9]. By Route of Administration - The parenteral route led the market in 2024 due to poor oral bioavailability of most peptides, with alternative delivery methods expected to grow at the highest CAGR [10]. By Synthesis Technology - The recombinant DNA technology segment held a 64.3% market share in 2024, favored for its ability to produce long and sustained peptides of higher purity [11]. Regional Insights - North America dominated the peptide therapeutics market with a 58.1% share in 2024, attributed to advanced clinical trials and a developed pharmaceutical sector, while the Asia Pacific region is expected to grow significantly due to increased healthcare expenditure and chronic disease prevalence [12]. Key Companies - Major companies in the peptide therapeutics market include Eli Lilly and Company, Amgen Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, AstraZeneca plc, and Sanofi S.A. [13][18].

Core Insights - Eupraxia Pharmaceuticals reported durable symptom and tissue responses for EP-104GI, with data observed up to 52 weeks following a single treatment, indicating its potential as an effective treatment for eosinophilic esophagitis (EoE) [1][2] - The company completed a public offering raising $80.5 million, which will support the advancement of the EP-104GI program and other pipeline developments [4][2] - The company has sufficient cash reserves to fund operations and pipeline development into the first half of 2028, with cash on hand reported at $89.0 million as of September 30, 2025 [6][7] Clinical Trial Updates - The Phase 1b/2a RESOLVE Trial showed that two-thirds of patients in Cohort 5 remained in clinical remission after treatment with EP-104GI, demonstrating long-term disease control [3] - The highest-dose cohort in the RESOLVE trial exhibited the largest improvements in tissue health outcomes and eosinophil reduction, with no additional safety concerns reported [2] Financial Performance - For Q3 2025, the company incurred a net loss of $6.4 million, slightly higher than the $6.0 million loss in Q3 2024, primarily due to increased research and development costs [5] - The company’s cash position improved significantly from $33.1 million at the end of Q4 2024 to $89.0 million as of September 30, 2025, allowing for continued funding of clinical trials and operational needs [6] Market and Operational Considerations - The company is monitoring the potential impacts of proposed tariffs on Canadian goods by the U.S. government and retaliatory tariffs by Canada, which could affect its operations [8][10] - Eupraxia manufactures its clinical supplies in the U.S. and maintains U.S. dollar balances to mitigate the impact of exchange rate fluctuations [9]

Financial Data and Key Metrics Changes - The company reported record royalty revenue of $236 million, a 52% increase year over year, contributing to total revenue of $354 million, which reflects a 22% growth year over year [4][27] - Adjusted EBITDA grew by 35% to $248 million, outpacing top-line growth, showcasing the strength of the royalty-based business model [4][30] - The company raised its full-year 2025 guidance, projecting total revenue of $1.3 billion to $1.375 billion, representing 28% to 35% growth over 2024 [7][31] Business Line Data and Key Metrics Changes - Darzalex Subcutaneous sales increased by 20% to $3.7 billion, with a significant market share gain of approximately 5.7 percentage points across all therapy lines [10][11] - Fesgo generated revenue of approximately $2.3 billion, reflecting a 54% year-over-year increase, with conversion from intravenous therapies reaching 51% [13] - Vyvgart Hytrulo saw total sales increase by 96% year-over-year to $1.13 billion, driven by the subcutaneous formulation enabling self-injection [14][16] Market Data and Key Metrics Changes - The company achieved 13 out of 15 growth catalysts year to date, including new product approvals and expanded indications [5] - The approval of Darzalex Subcutaneous for smoldering multiple myeloma in Europe is expected to expand its market reach significantly [6] - The subcutaneous formulation of Ocrevus is projected to represent an incremental $2 billion opportunity, with analysts estimating total brand sales to reach $10 billion by 2028 [18][19] Company Strategy and Development Direction - The acquisition of Electrovive aims to enhance at-home administration of biologic therapies, expanding the portfolio of drug delivery technologies [8] - The company is focused on patient-centric drug delivery solutions, leveraging its ENHANZE technology alongside new innovations like HyperCon [9] - The strategic goal is to maintain strong momentum in transforming the subcutaneous delivery landscape, with a robust pipeline of future royalty streams [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued strength of the core ENHANZE business and the accelerating momentum across the partner portfolio [34] - The company anticipates sustained royalty contributions from all products through at least 2030, ensuring a robust revenue stream [24] - Management highlighted the importance of ongoing discussions for new ENHANZE agreements, indicating strong interest from potential partners [48] Other Important Information - The company reported a strong balance sheet with cash and marketable securities of $702 million as of September 30, 2025, up from $596.1 million at the end of 2024 [28] - The net debt-to-EBITDA ratio was 0.9 times at the end of the third quarter, indicating a solid financial position [28] Q&A Session Summary Question: Thoughts on capital allocation and debt management - Management indicated a balanced approach to capital allocation, with plans to pay down debt while considering share repurchases and new acquisition opportunities [35][36] Question: Awareness of Electrovive technology among partners - Management noted that there is good awareness of the HyperCon technology among current partners, with strong support for potential collaboration [39] Question: Market growth sources for products - Management highlighted that market growth is coming from both share gains from other therapies and earlier use in treatment [40] Question: Future M&A opportunities - Management stated that while they are actively looking for new opportunities, it is unlikely there will be another acquisition this year following the Electrovive deal [42][43] Question: Updates on pipeline products - Management confirmed that there have not been any public updates from ViiV or Acumen recently, but they are awaiting further information [57]

Core Viewpoint - Halozyme Therapeutics, Inc. is focused on enhancing drug delivery technology through its ENHANZE platform, with significant developments including a recent acquisition and expectations for strong earnings growth [1][3][4]. Company Overview - Halozyme Therapeutics specializes in drug delivery technology, particularly through its ENHANZE platform, which allows for subcutaneous delivery of injectable biologics [1]. - The company's flagship product, Hylenex recombinant, is essential for improving subcutaneous fluid administration [1]. Financial Performance and Expectations - The consensus price target for HALO stock has fluctuated, currently at $74.5, down from $79.67 last quarter but up from $70.6 last year, indicating changing analyst expectations [2][5]. - Halozyme is preparing for its third-quarter earnings report, with expectations of robust royalty growth and a strong track record of surpassing earnings expectations [3][4]. Strategic Developments - The company has made a significant acquisition of Elektrofi, Inc. for an upfront payment of $750 million, which is expected to enhance its drug delivery offerings and influence its outlook for 2025 [3][5]. - The acquisition is anticipated to contribute to royalty revenue by 2030, targeting approved blockbuster mechanisms, thereby bolstering long-term growth prospects [4].